High-level Dolutegravir Resistance Selection on Dolutegravir/Lamivudine
- PMID: 38462967
- DOI: 10.1093/cid/ciae125
High-level Dolutegravir Resistance Selection on Dolutegravir/Lamivudine
Conflict of interest statement
Potential conflicts of interest. J. M. L. has received honoraria for lectures, presentations or speaker's bureaus from Janssen-Cilag, Gilead Sciences, Thera Technologies, MSD, and ViiV Healthcare, outside of the present work, and support from Gilead Sciences, Janssen Cilag, and ViiV Healthcare for attending meetings. J. M. L. also reports consulting fees from ViiV Healthcare, Gilead Sciences, MSD, and Janssen-Cilag; payment for expert testimony from Gilead Sciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Comment on
-
Insights in Dolutegravir-Resistance Pathways.Clin Infect Dis. 2024 Dec 17;79(6):1541-1542. doi: 10.1093/cid/ciae127. Clin Infect Dis. 2024. PMID: 38462992 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
